Lacidipina Tecnigen (Lacidipine)

Lacidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that is required for muscle contraction. This inhibition leads to vasodilation, a decrease in peripheral vascular resistance, and ultimately a reduction in systemic arterial blood pressure.

The specific dose of lacidipine is individualized by the prescribing clinician based on the patient’s blood pressure, response to therapy, and any co‑existing medical conditions. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety data for lacidipine in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Lacidipina Tecnigen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacidipine, as a dihydropyridine calcium‑channel blocker, offers potent vasodilation with a relatively low effect on heart rate, distinguishing it from non‑dihydropyridine agents. Compared with amlodipine, another dihydropyridine, lacidipine has a longer half‑life and may provide smoother blood‑pressure control, though clinical choice depends on individual patient factors.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Lacidipina Tecnigen is taken orally, usually once daily. It can be swallowed with or without food; however, consistent administration with respect to meals may help maintain stable plasma levels. Patients should follow the prescriber’s instructions regarding timing and any dietary considerations.

Serious adverse events, though uncommon, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as rash or angioedema, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, severe dizziness, jaundice or swelling of the face and throat.

Lacidipine is contraindicated in patients with known hypersensitivity to the drug or any other calcium‑channel blockers, in those with severe aortic stenosis, and in individuals with unstable angina or recent myocardial infarction where rapid blood‑pressure reduction could be harmful. Clinicians should also exercise caution in patients with significant liver or kidney disease.